Hcc
KEYNOTE-224:
Open-label study in patients with HCC, previously treated with sorafenib, an anti-angiogenic TKI
N=104 participants
The median duration of follow-up – 12·3 months (IQR 7·6–15·1)1
Objective Response1
KEYNOTE-224:
Open-label study in patients with HCC, previously treated with sorafenib, an anti-angiogenic TKI
N=104 participants
The median duration of follow-up – 12·3 months (IQR 7·6–15·1)1